- Home
- BDSX
BDSX
Biodesix Inc.
as of 03-06-2026 3:58pm EST
$18.75
+$2.89
+18.22%
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | LOUISVILLE |
| Market Cap: | 122.0M | IPO Year: | 2020 |
| Target Price: | $32.50 | AVG Volume (30 days): | 129.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.67 | EPS Growth: | -1315.15 |
| 52 Week Low/High: | $0.25 - $17.40 | Next Earning Date: | 05-21-2026 |
| Revenue: | $88,499,000 | Revenue Growth: | 24.08% |
| Revenue Growth (this year): | 23.35% | Revenue Growth (next year): | 19.33% |
| P/E Ratio: | -3.36 | Index: | N/A |
| Free Cash Flow: | -23530000.0 | FCF Growth: | N/A |
AI-Powered BDSX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
buy
Model Accuracy: 69.87%
69.87%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Biodesix Inc. (BDSX)
Vazquez Chris
Sell
Chief Accounting Officer
BDSX Feb 23, 2026
Avg Cost/Share
$12.78
Shares
211
Total Value
$2,695.65
Owned After
1,586
SEC Form 4
Pestano Gary Anthony
Sell
Chief Development Officer
BDSX Feb 23, 2026
Avg Cost/Share
$12.78
Shares
556
Total Value
$7,103.23
Owned After
10,359
SEC Form 4
Cowie Robin Harper
Sell
CFO, Sec'y & Treasurer
BDSX Feb 23, 2026
Avg Cost/Share
$12.78
Shares
535
Total Value
$6,834.95
Owned After
16,231
SEC Form 4
O'Kane Kieran
Sell
Chief Commercial Officer
BDSX Feb 23, 2026
Avg Cost/Share
$12.78
Shares
535
Total Value
$6,834.95
Owned After
9,819
SEC Form 4
Hutton Scott
Sell
President & CEO
BDSX Feb 23, 2026
Avg Cost/Share
$12.78
Shares
1,490
Total Value
$19,035.64
Owned After
48,767
SEC Form 4
Vazquez Chris
Sell
Chief Accounting Officer
BDSX Feb 10, 2026
Avg Cost/Share
$10.08
Shares
101
Total Value
$1,018.49
Owned After
1,586
SEC Form 4
Pestano Gary Anthony
Sell
Chief Development Officer
BDSX Feb 10, 2026
Avg Cost/Share
$10.08
Shares
540
Total Value
$5,445.41
Owned After
10,359
SEC Form 4
Cowie Robin Harper
Sell
CFO, Sec'y & Treasurer
BDSX Feb 10, 2026
Avg Cost/Share
$10.08
Shares
941
Total Value
$9,489.14
Owned After
16,231
SEC Form 4
O'Kane Kieran
Sell
Chief Commercial Officer
BDSX Feb 10, 2026
Avg Cost/Share
$10.08
Shares
584
Total Value
$5,889.11
Owned After
9,819
SEC Form 4
Hutton Scott
Sell
President & CEO
BDSX Feb 10, 2026
Avg Cost/Share
$10.08
Shares
3,559
Total Value
$35,889.31
Owned After
48,767
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Vazquez Chris | BDSX | Chief Accounting Officer | Feb 23, 2026 | Sell | $12.78 | 211 | $2,695.65 | 1,586 | |
| Pestano Gary Anthony | BDSX | Chief Development Officer | Feb 23, 2026 | Sell | $12.78 | 556 | $7,103.23 | 10,359 | |
| Cowie Robin Harper | BDSX | CFO, Sec'y & Treasurer | Feb 23, 2026 | Sell | $12.78 | 535 | $6,834.95 | 16,231 | |
| O'Kane Kieran | BDSX | Chief Commercial Officer | Feb 23, 2026 | Sell | $12.78 | 535 | $6,834.95 | 9,819 | |
| Hutton Scott | BDSX | President & CEO | Feb 23, 2026 | Sell | $12.78 | 1,490 | $19,035.64 | 48,767 | |
| Vazquez Chris | BDSX | Chief Accounting Officer | Feb 10, 2026 | Sell | $10.08 | 101 | $1,018.49 | 1,586 | |
| Pestano Gary Anthony | BDSX | Chief Development Officer | Feb 10, 2026 | Sell | $10.08 | 540 | $5,445.41 | 10,359 | |
| Cowie Robin Harper | BDSX | CFO, Sec'y & Treasurer | Feb 10, 2026 | Sell | $10.08 | 941 | $9,489.14 | 16,231 | |
| O'Kane Kieran | BDSX | Chief Commercial Officer | Feb 10, 2026 | Sell | $10.08 | 584 | $5,889.11 | 9,819 | |
| Hutton Scott | BDSX | President & CEO | Feb 10, 2026 | Sell | $10.08 | 3,559 | $35,889.31 | 48,767 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
AI Prediction SELL
1D
-5.91%
$13.38
5D
-10.12%
$12.78
20D
-8.33%
$13.04
Price: $14.22 Prob +5D: 0% AUC: 1.000
0001193125-26-076521
8-K
false000143972500014397252026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 26, 2026 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware
001-39659
20-3986492
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
919 West Dillon Rd Louisville, Colorado (Address of Principal Executive Office)
80027 (Zip Code)
Registrant’s telephone number, including area code: (303) 417-0500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value of $0.001 per share
BDSX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On February 26, 2026, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in Item 2.02 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document or filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
No.
Exhibit
99.1
Press Release issued by Biodesix, Inc. dated February 26, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 26, 2026
BIODESIX, INC.
By:
/s/ Robin Harper Cowie
Name:
Robin Harper Cowie
Title:
Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K/A SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K/A SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
-5.91%
$13.38
5D
-10.12%
$12.78
20D
-8.33%
$13.04
Price: $14.22 Prob +5D: 0% AUC: 1.000
0001193125-26-010114
8-K/A
false000143972500014397252026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 12, 2026 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware
001-39659
20-3986492
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
919 West Dillon Rd Louisville, Colorado (Address of Principal Executive Office)
80027 (Zip Code)
Registrant’s telephone number, including area code: (303) 417-0500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value of $0.001 per share
BDSX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note Biodesix, Inc. (the Company) is filing this Form 8-K/A to its Current Report on Form 8-K filed on January 12, 2026 solely to recharacterize the press release announcing certain preliminary and unaudited financial results of the Company for the fourth quarter and year ended December 31, 2025 as filed rather than furnished. No other changes have been made. Item 2.02. Results of Operations and Financial Condition. On January 12, 2026, the Company issued a press release announcing certain preliminary and unaudited financial results of the Company for the fourth quarter and year ended December 31, 2025. A copy of the press release is included as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in this Item 2.02 of this Current Report on Form 8-K/A, including Exhibit 99.1 hereto, is being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and shall be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, to the extent specifically incorporated by reference therein. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
No.
Exhibit
99.1
Press Release issued by Biodesix, Inc. dated January 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 12, 2026
BIODESIX, INC.
By:
/s/ Robin Harper Cowie
Name:
Robin Harper Cowie
Title:
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0001193125-25-262508
8-K
0001439725false00014397252025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware
001-39659
20-3986492
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
919 West Dillon Rd Louisville, Colorado (Address of Principal Executive Office)
80027 (Zip Code)
Registrant’s telephone number, including area code: (303) 417-0500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value of $0.001 per share
BDSX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On November 3, 2025, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in Item 2.02 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document or filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
No.
Exhibit
99.1
Press Release issued by Biodesix, Inc. dated November 3, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 3, 2025
BIODESIX, INC.
By:
/s/ Robin Harper Cowie
Name:
Robin Harper Cowie
Title:
Chief Financial Officer
Latest Biodesix Inc. News
BDSX Breaking Stock News: Dive into BDSX Ticker-Specific Updates for Smart Investing
Zacks
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
Biodesix (BDSX) Q4 2025 Earnings Call Transcript
Compare BDSX vs Leading Stocks
See how BDSX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BDSX Biodesix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.